{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"DoR is defined as the time from first documented evidence or PR or better until progressive disease per IMWG or death due to progressive disease among participants who achieve confirmed partial response or better.","groups":[{"description":"Participants with RRMM received 1.9 milligram (mg)/kilogram (kg) belantamab mafodotin intravenous (IV) infusion as powder for solution once every 3 weeks (Q3W) infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 8 mg OX40 IV solution 1 hour after belantamab mafodotin end of infusion (EOI) on day 1 of 21-day cycles.","id":"OG000","title":"1.9 mg/kg Belantamab Mafodotin + 8mg OX40"},{"description":"Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion as powder for solution Q3W infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 8 mg OX40 IV solution 1 hour after belantamab mafodotin EOI on day 1 of 21-day cycles.","id":"OG001","title":"2.5 mg/kg Belantamab Mafodotin + 8mg OX40"}],"populationDescription":"Safety Population included all participants who received at least 1 dose of any component of the combination therapy.\n\nNo participants were enrolled in CE Phase as study got terminated.","reportingStatus":"POSTED","timeFrame":"Up to 170 weeks","title":"CE Phase: Duration of Response (DoR)","type":"SECONDARY"}